Characteristics of ASCT (n = 36)
| . | n . | % . |
|---|---|---|
| Age, median (range), y | 65 | 20-75 |
| Sex | ||
| Male | 14 | 39 |
| Female | 22 | 61 |
| HCT-CI | ||
| 0 | 10 | 37 |
| 1-2 | 5 | 19 |
| ≥3 | 12 | 44 |
| NA | 9 | — |
| AML subtype | ||
| MRC-AML | 26 | 72 |
| MDS-AML | 11 | 31 |
| CMML-AML | 1 | 3 |
| t-AML | 9 | 25 |
| Others | 1 | 3 |
| Disease status at time of ASCT | ||
| CR | 32 | 89 |
| CRi | 1 | 3 |
| PR | 3 | 8 |
| MRD status after CPX-351 induction | ||
| Negative | 8 | 57 |
| Positive | 6 | 43 |
| NA | 22 | — |
| Conditioning regimen | ||
| RIC | 33 | 92 |
| MAC | 3 | 8 |
| Donor | ||
| Matched related donor | 9 | 25 |
| Matched unrelated donor | 16 | 44 |
| Mismatched donor | 5 | 14 |
| Haploidentical donor | 6 | 17 |
| Stem cell source | ||
| Bone marrow | 2 | 6 |
| Peripheral blood | 34 | 94 |
| . | n . | % . |
|---|---|---|
| Age, median (range), y | 65 | 20-75 |
| Sex | ||
| Male | 14 | 39 |
| Female | 22 | 61 |
| HCT-CI | ||
| 0 | 10 | 37 |
| 1-2 | 5 | 19 |
| ≥3 | 12 | 44 |
| NA | 9 | — |
| AML subtype | ||
| MRC-AML | 26 | 72 |
| MDS-AML | 11 | 31 |
| CMML-AML | 1 | 3 |
| t-AML | 9 | 25 |
| Others | 1 | 3 |
| Disease status at time of ASCT | ||
| CR | 32 | 89 |
| CRi | 1 | 3 |
| PR | 3 | 8 |
| MRD status after CPX-351 induction | ||
| Negative | 8 | 57 |
| Positive | 6 | 43 |
| NA | 22 | — |
| Conditioning regimen | ||
| RIC | 33 | 92 |
| MAC | 3 | 8 |
| Donor | ||
| Matched related donor | 9 | 25 |
| Matched unrelated donor | 16 | 44 |
| Mismatched donor | 5 | 14 |
| Haploidentical donor | 6 | 17 |
| Stem cell source | ||
| Bone marrow | 2 | 6 |
| Peripheral blood | 34 | 94 |
HCT-CI, hematopoietic cell transplant comorbidity index; MAC, myeloablative conditioning; NA, not available; PR, partial response; RIC, reduced-intensity conditioning.